Natco Pharma
881.60
+3.40(+0.39%)
Market Cap₹15,729.40 Cr
PE Ratio8.37
IndustryHealthcare
Company Performance:
1D+0.39%
1M+1.78%
6M-40.30%
1Y-24.81%
5Y+40.24%
View Company Insightsright
Latest news about Natco Pharma
Natco Pharma Receives FDA Observations at Hyderabad Facilities 5 hours ago Yesterday
Natco Pharma's pharmaceutical division in Kothur, Hyderabad, received seven observations under Form 483 from the FDA. The company's API facility in Mekaguda, Hyderabad, received one procedural observation. Natco Pharma has expressed confidence in addressing these issues within the stipulated timeline.
Natco Pharma's Kothur Facility Receives Seven Observations in US FDA Inspection 7 hours ago Yesterday
Natco Pharma's API Facility Clears U.S. FDA Inspection with Minor Observation 3 days ago
NATCO Pharma Receives USFDA Observation at Hyderabad API Facility; Q4 Profit Misses Estimates 6 days ago
NATCO Pharma's API Plant Clears U.S. FDA Inspection with Minor Observation 6 days ago
More news about Natco Pharma
29May 25
Natco Pharma Reports Robust Q4 Results: Net Profit Rises to ₹410 Crore
Natco Pharma announced impressive Q4 financial results, with net profit rising to ₹410.00 crore, up 6.22% year-over-year. Revenue increased by 14.23% to ₹1,220.00 crore. The company's quarterly net profit showed a significant 208.27% growth from the previous quarter. Annual performance was even more robust, with net profit up 94.09% to ₹1,388.30 crore and revenue increasing 46.78% to ₹4,126.90 crore. Operating Profit Margin improved to 43.80% from 34.56% last year.
28May 25
Natco Pharma's Q4 Profit Rises 5.3%, Falls Short of Expectations
Natco Pharma's Q4 results show a 5.3% increase in net profit to Rs 407.00 crore, with revenue rising 14.3% to Rs 1,221.00 crore. However, the company faced significant year-over-year declines in key metrics, including an 18.16% drop in revenue and a 37.75% decrease in net profit for Q4. Operating profit margin fell sharply to 8.17% from 35.34% last year. The company projects a 20% decline in revenue and a 30% drop in profit, citing increased pressures in the US market and higher R&D expenses.
08Apr 25
Natco Pharma's Risdiplam Launch Faces Legal Hurdles
Natco Pharma's plan to launch Risdiplam in India is currently on hold due to a legal dispute with Roche. The Delhi High Court initially ruled in Natco's favor, but Roche has appealed. The Appellate Bench has ordered a status quo, delaying the launch. Natco plans to price Risdiplam at ₹15900.00 MRP with additional discounts for certain patients if cleared for launch. The company is awaiting the Appellate Bench's decision before proceeding.
08Apr 25
Natco Pharma Awaits Court Clarity on Risdiplam Launch Amid Roche's Appeal
Natco Pharma is embroiled in a legal battle with Roche over the launch of Risdiplam in India. The Delhi High Court's appellate bench has ordered a status quo, delaying the launch. Despite this, Natco has announced its pricing strategy, setting the MRP at ₹15,900.00 and planning a patient access program for discounts. The company awaits legal clarity before proceeding with the launch, which has garnered significant interest from investors and patients.
25Mar 25
Natco Pharma Wins Legal Battle: Delhi HC Dismisses Roche's Plea on Risdiplam Patent
The Delhi High Court has rejected Roche's plea to prevent Natco Pharma from manufacturing and selling Risdiplam, a drug used to treat spinal muscular atrophy (SMA). This ruling allows Natco to continue its operations related to Risdiplam, despite Roche's claims of patent infringement. The decision could impact the availability and pricing of this critical SMA treatment in the Indian market.
24Mar 25
Natco Pharma Gains Upper Hand in Risdiplam Patent Case Against Roche
The Delhi High Court has dismissed Roche's plea to block Natco Pharma regarding the patent for Risdiplam, a drug used to treat spinal muscular atrophy (SMA). This ruling could allow Natco Pharma to manufacture and market its version of Risdiplam, potentially increasing accessibility and affordability of the drug for SMA patients in India and other markets. The decision marks a significant setback for Roche and could have far-reaching implications for the availability and pricing of SMA treatments.
Natco Pharma
881.60
+3.40
(+0.39%)
1 Year Returns:-24.81%
Industry Peers
Sun Pharmaceutical
1,647.60
(-0.02%)
Divis Laboratories
6,493.00
(-0.86%)
Cipla
1,484.00
(-0.94%)
Dr Reddys Laboratories
1,326.10
(+0.97%)
Torrent Pharmaceuticals
3,164.00
(-1.95%)
Mankind Pharma
2,325.20
(-1.40%)
Zydus Life Science
950.05
(-0.86%)
Lupin
1,931.80
(-1.14%)
Abbott
31,030.00
(-1.69%)
Aurobindo Pharma
1,082.50
(-2.06%)